Category Archives: Eur Respir J

Costly comorbidities of COPD: the ignored side of the coin?

Related Articles
Costly comorbidities of COPD: the ignored side of the coin?
Eur Respir J. 2017 Jul;50(1):
Authors: van Boven JFM
PMID: 28751418 [PubMed – in process]

Continue reading

Posted in Eur Respir J | Tagged , | Leave a comment

Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

Eur Respir J. 2015 Nov 19;

Authors: Tiberi S, D’Ambrosio L, De Lorenzo S,…

Continue reading

Posted in Eur Respir J | Tagged | Leave a comment

Clinical features of large cell neuroendocrine carcinoma: a population-based overview.

Clinical features of large cell neuroendocrine carcinoma: a population-based overview.

Eur Respir J. 2015 Nov 5;

Authors: Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ,…

Continue reading

Posted in Eur Respir J | Tagged | Leave a comment

The minimal important difference for the St George’s Respiratory Questionnaire in patients with severe COPD.

Related Articles

The minimal important difference for the St George’s Respiratory Questionnaire in patients with severe COPD.

Eur Respir J. 2015 Oct 22;

Authors: Welling JB, Hartman JE, Ten Hacken NH, Klooster K, Slebos DJ

Abstract
The St George’s Respiratory Questionnaire (SGRQ) is a validated, commonly used questionnaire for measuring quality of life in patients with chronic obstructive pulmonary disease (COPD). The current established minimal important difference (MID) for SGRQ scores in an average COPD population is -4 units. However, for patients with severe COPD, the MID has not been thoroughly validated. We re-determined the SGRQ MID for this patient group.115 severe COPD patients (forced expiratory volume in 1 s (FEV1) 26±9% of predicted, SGRQ score 62±11 units; mean±sd,) who participated in seven different bronchoscopic lung volume reduction clinical trials were included in the analysis. Anchor- and distribution-based methods were used to define the MID for SGRQ scores. FEV1, 6-min walk distance and residual volume were used as anchors.Combining both anchor- and distribution-based methods, we identified a SGRQ MID of -8.3 units at 1 month and -7.1 units at 6 months.This study proposes an alternative SGRQ MID for patients with severe COPD of -8.3 units at 1 month and -7.1 units at 6 months follow-up after intervention. Our new MID estimates could be applied for both interpreting SGRQ outcomes as well as sample size determination in future clinical trials investigating interventions in severe COPD patients.

PMID: 26493797 [PubMed – as supplied by publisher]

Continue reading

Posted in Eur Respir J | Tagged | Leave a comment

Guidance for the regulatory status of allergen extracts in clinical trials.

Related Articles

Guidance for the regulatory status of allergen extracts in clinical trials.

Eur Respir J. 2015 Oct;46(4):1223-5

Authors: Diamant Z, van Maaren…

Continue reading

Posted in Eur Respir J | Tagged | Leave a comment

Anti-inflammatory effects of targeted lung denervation in patients with COPD.

Anti-inflammatory effects of targeted lung denervation in patients with COPD.
Eur Respir J. 2015 Sep 4;
Authors: Kistemaker LE, Slebos DJ, Meurs H, Kerstjens HA, Gosens R
PMID: 26341988 [PubMed – as supplied … Continue reading

Posted in Eur Respir J | Leave a comment

The different faces of the asthma-COPD overlap syndrome.

Related Articles
The different faces of the asthma-COPD overlap syndrome.
Eur Respir J. 2015 Sep;46(3):587-90
Authors: Postma DS, van den Berge M
PMID: 26324685 [PubMed – in process]

Continue reading

Posted in Eur Respir J | Leave a comment

Unravelling the complexity of COPD by microRNAs: it’s a small world after all.

Related Articles
Unravelling the complexity of COPD by microRNAs: it’s a small world after all.
Eur Respir J. 2015 Aug 6;
Authors: Osei ET, Florez-Sampedro L, Timens W, Postma DS, Heijink IH, Brandsma CA
Abstr… Continue reading

Posted in Eur Respir J | Leave a comment

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.
Eur Respir J. 2015 Jul 9;
Authors: Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaa… Continue reading

Posted in Eur Respir J | Leave a comment

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.

Eur Respir J. 2015 Jul 9;

Authors: Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AM, van der Ende A, Grobbee DE, Sanders EA, Sato R, Verheij TJ, Vissink CE, Bonten MJ, de Wit GA

Abstract
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13-vaccination in the Netherlands.Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13-vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13-vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted.The ICER for base-case was €8650 per QALY (95% CI 5750-17 100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of €2900. Further extension to include medium- and high-risk individuals aged ≥18 years yielded an ICER of €3100.PCV13-vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.

PMID: 26160871 [PubMed – as supplied by publisher]

Continue reading

Posted in Eur Respir J | Leave a comment

Effects of ageing and smoking on pulmonary computed tomography scans using parametric response mapping.

Related Articles

Effects of ageing and smoking on pulmonary computed tomography scans using parametric response mapping.

Eur Respir J. 2015 Jun 25;

Authors: …

Continue reading

Posted in Eur Respir J | Tagged | Leave a comment

Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study.

Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study.
Eur Respir J. 2015 Jun;45(6):1534-8
Authors: Postma DS, Brightling C, Fabbri L, van der Molen T, Nicolini G, … Continue reading

Posted in Eur Respir J | Leave a comment

Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and D.

Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and D.

Eur Respir J. 2015 May 28;

Authors: Anzueto A, Jenkins CR, Make BJ, Lindberg M, Calverley PM, Fagerås M, Postma DS, Rennard SI, Tashkin DP

PMID: 26022947 [PubMed – as supplied by publisher]

Continue reading

Posted in Eur Respir J | Leave a comment

The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease.

The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease.

Eur Respir J. 2015 May 28;

Authors: Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M, Dobbels F, Ivanoff N, de Boer WI, van der Molen T, Kulich K, Serra I, Basagaña X, Troosters T, Puhan MA, Karlsson N, Garcia-Aymerich J, PROactive consortium

Abstract
No current patient-centred instrument captures all dimensions of physical activity in chronic obstructive pulmonary disease (COPD). Our objective was item reduction and initial validation of two instruments to measure physical activity in COPD. Physical activity was assessed in a 6-week, randomised, two-way cross-over, multicentre study using PROactive draft questionnaires (daily and clinical visit versions) and two activity monitors. Item reduction followed an iterative process including classical and Rasch model analyses, and input from patients and clinical experts. 236 COPD patients from five European centres were included. Results indicated the concept of physical activity in COPD had two domains, labelled “amount” and “difficulty”. After item reduction, the daily PROactive instrument comprised nine items and the clinical visit contained 14. Both demonstrated good model fit (person separation index >0.7). Confirmatory factor analysis supported the bidimensional structure. Both instruments had good internal consistency (Cronbach’s α>0.8), test-retest reliability (intraclass correlation coefficient ≥0.9) and exhibited moderate-to-high correlations (r>0.6) with related constructs and very low correlations (r<0.3) with unrelated constructs, providing evidence for construct validity. Daily and clinical visit “PROactive physical activity in COPD” instruments are hybrid tools combining a short patient-reported outcome questionnaire and two activity monitor variables which provide simple, valid and reliable measures of physical activity in COPD patients.

PMID: 26022965 [PubMed – as supplied by publisher]

Continue reading

Posted in Eur Respir J | Leave a comment

Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.

Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.
Eur Respir J. 2015 May 28;
Authors: van der Paardt AF, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B,… Continue reading

Posted in Eur Respir J | Leave a comment

Increased serum levels of LL37, HMGB1 and S100A9 during exacerbation in COPD patients.

Increased serum levels of LL37, HMGB1 and S100A9 during exacerbation in COPD patients.
Eur Respir J. 2015 May;45(5):1482-5
Authors: Pouwels SD, Nawijn MC, Bathoorn E, Riezebos-Brilman A, van Oosterhout AJ, Kerstjens … Continue reading

Posted in Eur Respir J | Leave a comment

An interlaboratory quality control programme for the measurement of tuberculosis drugs.

Related Articles
An interlaboratory quality control programme for the measurement of tuberculosis drugs.
Eur Respir J. 2015 Apr 16;
Authors: Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR… Continue reading

Posted in Eur Respir J | Leave a comment

Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension.

Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension.

Eur Respir J. 2015 Apr 2;

Authors: Jacobs W, Konings TC, Heymans MW, Boonstra A, Bogaard HJ, van Rossum AC, Vonk Noordegraaf A

Abstract
Exclusion of pulmonary hypertension secondary to left-sided heart disease (left heart failure (LHF)) is pivotal in the diagnosis of pulmonary arterial hypertension (PAH). In case of doubt, invasive measurements are recommended. The aim of the present study was to investigate whether it is possible to diagnose LHF using noninvasive parameters in a population suspected of PAH. 300 PAH and 80 LHF patients attended our pulmonary hypertension clinic before August 2010, and were used to build the predictive model. 79 PAH and 55 LHF patients attended our clinic from August 2010, and were used for prospective validation. A medical history of left heart disease, S deflection in V1 plus R deflection in V6 in millimetres on ECG, and left atrial dilation or left valvular heart disease that is worse than mild on echocardiography were independent predictors of LHF. The derived risk score system showed good predictive characteristics: R(2)=0.66 and area under the curve 0.93. In patients with a risk score ⩾72, there is 100% certainty that the cause of pulmonary hypertension is LHF. Using this risk score system, the number of right heart catheterisations in LHF may be reduced by 20%. In a population referred under suspicion of PAH, a predictive model incorporating medical history, ECG and echocardiography data can diagnose LHF noninvasively in a substantial percentage of cases.

PMID: 25837029 [PubMed – as supplied by publisher]

Continue reading

Posted in Eur Respir J | Leave a comment

Salmeterol/fluticasone combination instead of indacaterol or vice-versa?

Salmeterol/fluticasone combination instead of indacaterol or vice-versa?
Eur Respir J. 2015 Apr;45(4):1188-9
Authors: Rossi A, van der Molen T, Del Olmo R, Wehbe L
PMID: 25829434 [PubMed – in process]

Continue reading

Posted in Eur Respir J | Tagged , | Leave a comment

Inhibition of Pim1 kinase reduces viral replication in primary bronchial epithelial cells.

Inhibition of Pim1 kinase reduces viral replication in primary bronchial epithelial cells.
Eur Respir J. 2015 Mar 5;
Authors: de Vries M, Smithers NP, Howarth PH, Nawijn MC, Davies DE
PMID: 25745039 [PubMed -… Continue reading

Posted in Eur Respir J | Leave a comment